Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Anglaret

Showing results (151-160 of 161) with videos related to

Pageof 17
Sort By:
The Lancet. HIV|May 13, 2024
Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trialSerge P Eholie, Didier K Ekouevi, Corine Chazallon, et al.
The Lancet. HIV|October 12, 2019
Implementation of an intensive adherence intervention in patients with second-line antiretroviral therapy failure in four west African countries with little access to genotypic resistance testing: a prospective cohort studySerge P Eholie, Raoul Moh, Aïda Benalycherif, et al.
Journal of the Pediatric Infectious Diseases Society|August 21, 2024
Presentation and Outcomes of Lassa Fever in Children in Nigeria: A Prospective Cohort Study (LASCOPE)Alexandre Duvignaud, Ijeoma C Etafo, Marie Jaspard, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 3, 2016
Resurgence of Ebola Virus Disease in Guinea Linked to a Survivor With Virus Persistence in Seminal Fluid for More Than 500 DaysBoubacar Diallo, Daouda Sissoko, Nicholas J Loman, et al.
Travel Medicine and Infectious Disease|January 25, 2020
Lassa fever clinical course and setting a standard of care for future randomized trials: A protocol for a cohort study of Lassa-infected patients in Nigeria (LASCOPE)Alexandre Duvignaud, Marie Jaspard, Ijeoma Chukwudumebi Etafo, et al.
The Lancet. Global Health|December 14, 2016
Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling studyDaouda Sissoko, Sophie Duraffour, Romy Kerber, et al.
The Lancet. Global Health|October 14, 2017
Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trialAnani Badje, Raoul Moh, Delphine Gabillard, et al.
The Journal of Infectious Diseases|February 22, 2019
Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retrospective Observational StudyRomy Kerber, Eva Lorenz, Sophie Duraffour, et al.
The New England Journal of Medicine|July 21, 2015
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa, Christine Danel, Raoul Moh, et al.
Plos Medicine|April 6, 2016
Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in GuineaDaouda Sissoko, Cedric Laouenan, Elin Folkesson, et al.
Pageof 17

Showing results (151-160 of 161) with videos related to

Sort By:
Pageof 17
The Lancet. HIV|May 13, 2024
Efficacy and safety of three antiretroviral therapy regimens for treatment-naive African adults living with HIV-2 (FIT-2): a pilot, phase 2, non-comparative, open-label, randomised controlled trialSerge P Eholie, Didier K Ekouevi, Corine Chazallon, et al.
The Lancet. HIV|October 12, 2019
Implementation of an intensive adherence intervention in patients with second-line antiretroviral therapy failure in four west African countries with little access to genotypic resistance testing: a prospective cohort studySerge P Eholie, Raoul Moh, Aïda Benalycherif, et al.
Journal of the Pediatric Infectious Diseases Society|August 21, 2024
Presentation and Outcomes of Lassa Fever in Children in Nigeria: A Prospective Cohort Study (LASCOPE)Alexandre Duvignaud, Ijeoma C Etafo, Marie Jaspard, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 3, 2016
Resurgence of Ebola Virus Disease in Guinea Linked to a Survivor With Virus Persistence in Seminal Fluid for More Than 500 DaysBoubacar Diallo, Daouda Sissoko, Nicholas J Loman, et al.
Travel Medicine and Infectious Disease|January 25, 2020
Lassa fever clinical course and setting a standard of care for future randomized trials: A protocol for a cohort study of Lassa-infected patients in Nigeria (LASCOPE)Alexandre Duvignaud, Marie Jaspard, Ijeoma Chukwudumebi Etafo, et al.
The Lancet. Global Health|December 14, 2016
Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling studyDaouda Sissoko, Sophie Duraffour, Romy Kerber, et al.
The Lancet. Global Health|October 14, 2017
Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trialAnani Badje, Raoul Moh, Delphine Gabillard, et al.
The Journal of Infectious Diseases|February 22, 2019
Laboratory Findings, Compassionate Use of Favipiravir, and Outcome in Patients With Ebola Virus Disease, Guinea, 2015-A Retrospective Observational StudyRomy Kerber, Eva Lorenz, Sophie Duraffour, et al.
The New England Journal of Medicine|July 21, 2015
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa, Christine Danel, Raoul Moh, et al.
Plos Medicine|April 6, 2016
Correction: Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in GuineaDaouda Sissoko, Cedric Laouenan, Elin Folkesson, et al.
Pageof 17